{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Apricoxib",
  "nciThesaurus": {
    "casRegistry": "197904-84-0",
    "chebiId": "",
    "chemicalFormula": "C19H20N2O3S",
    "definition": "An orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. Apricoxib-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis.",
    "fdaUniiCode": "5X5HB3VZ3Z",
    "identifier": "C74021",
    "preferredName": "Apricoxib",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C80509"
    ],
    "synonyms": [
      "APRICOXIB",
      "Apricoxib",
      "COX-2 Inhibitor TG01",
      "CS-706",
      "R-109339",
      "TG01",
      "TP2001"
    ]
  }
}